[Pharmacological studies on a new penicillin group antibiotic, sodium 6-[D(-)-alpha-(4-ethyl-2, 3-dioxo-1-piperazinecarboxamido)-alpha-phenylacetamido] penicillanate (T-1220). I. Effect on central and peripheral nervous systems (author's transl)].
D000667:Ampicillin / Q000494:pharmacology; D000700:Analgesics; D000779:Anesthetics, Local; D000818:Animals; D000927:Anticonvulsants; D001522:Behavior, Animal / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D002490:Central Nervous System / Q000187:drug effects*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004569:Electroencephalography; D004639:Emetics; D005260:Female; D008124:Locomotion / Q000187:drug effects; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009469:Neuromuscular Junction / Q000187:drug effects; D010406:Penicillins / Q000494:pharmacology*; D010424:Pentobarbital / Q000494:pharmacology; D010525:Peripheral Nerves / Q000187:drug effects*; D010879:Piperazines / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D012018:Reflex / Q000187:drug effects; D012890:Sleep / Q000187:drug effects; D013116:Spinal Cord / Q000187:drug effects
D000700:Analgesics; D000779:Anesthetics, Local; D000927:Anticonvulsants; D004639:Emetics; D010406:Penicillins; D010879:Piperazines; D000667:Ampicillin; D010424:Pentobarbital